JP2006510677A - ハロゲン化キサンテンを使用する超音波造影 - Google Patents
ハロゲン化キサンテンを使用する超音波造影 Download PDFInfo
- Publication number
- JP2006510677A JP2006510677A JP2004559466A JP2004559466A JP2006510677A JP 2006510677 A JP2006510677 A JP 2006510677A JP 2004559466 A JP2004559466 A JP 2004559466A JP 2004559466 A JP2004559466 A JP 2004559466A JP 2006510677 A JP2006510677 A JP 2006510677A
- Authority
- JP
- Japan
- Prior art keywords
- halogenated xanthene
- tissue
- ultrasound
- halogenated
- rose bengal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 title claims abstract 10
- 238000012285 ultrasound imaging Methods 0.000 title abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 17
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930187593 rose bengal Natural products 0.000 claims abstract description 11
- 229940081623 rose bengal Drugs 0.000 claims abstract description 11
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 238000003384 imaging method Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 238000002604 ultrasonography Methods 0.000 claims description 14
- 239000002961 echo contrast media Substances 0.000 claims description 11
- 239000002872 contrast media Substances 0.000 abstract description 2
- 150000003732 xanthenes Chemical group 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WBLLWHYYHNSTFH-UHFFFAOYSA-N 2',4',5',7'-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C(Cl)=C1OC1=C(Cl)C(O)=C(Cl)C=C21 WBLLWHYYHNSTFH-UHFFFAOYSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- ZDTNHRWWURISAA-UHFFFAOYSA-N 4',5'-dibromo-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(Br)=C1OC1=C(Br)C(O)=CC=C21 ZDTNHRWWURISAA-UHFFFAOYSA-N 0.000 description 1
- WLHLYHWMNUCWEV-UHFFFAOYSA-N 4',5'-dichloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(Cl)=C1OC1=C(Cl)C(O)=CC=C21 WLHLYHWMNUCWEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
- FHRUGNCCGSEPPE-UHFFFAOYSA-L disodium;2-(4,5-dibromo-3,6-dioxido-9h-xanthen-9-yl)benzoate;hydron Chemical compound [H+].[Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1C2=CC=C([O-])C(Br)=C2OC2=C(Br)C([O-])=CC=C21 FHRUGNCCGSEPPE-UHFFFAOYSA-L 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZBQZBWKNGDEDOA-UHFFFAOYSA-N eosin B Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC([N+]([O-])=O)=C(O)C(Br)=C1OC1=C2C=C([N+]([O-])=O)C(O)=C1Br ZBQZBWKNGDEDOA-UHFFFAOYSA-N 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- UKZQEOHHLOYJLY-UHFFFAOYSA-M ethyl eosin Chemical compound [K+].CCOC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 UKZQEOHHLOYJLY-UHFFFAOYSA-M 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- -1 xanthene halide Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/008—Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
好ましい実施形態の場合には、このような超音波造影剤の主要成分は、ハロゲン化キサンテンまたはハロゲン化キサンテンの機能的誘導体である。もう1つの好ましい実施形態の場合には、ハロゲン化キサンテンは、ローズ・ベンガルまたはローズ・ベンガルの機能的誘導体である。
もう1つの好ましい実施形態の場合には、この薬剤はハロゲン化キサンテン、ローズ・ベンガルを含む。
上記説明は単に例示としてのものであって、本出願の発明の範囲を制限するものではない。
新規および特許により保護したいものについては、添付の特許請求の範囲に記載する。
Claims (6)
- 人間または動物の組織を画像形成するための方法であって、
超音波造影剤を患者に投与するステップであって、前記超音波造影剤の一部が当該組織内に残留するステップと、
前記組織を識別するために超音波により前記組織を画像形成するステップとを含み、
前記超音波造影剤がハロゲン化キサンテンであることを特徴とする方法。 - 前記ハロゲン化キサンテンが、約0.001%より高く約20%より低い濃度で存在することを特徴とする請求項1に記載の方法。
- 前記ハロゲン化キサンテンがローズ・ベンガルであることを特徴とする請求項1に記載の方法。
- 少なくとも1つのハロゲン化キサンテンを主要有効成分として含有する薬剤であって、前記薬剤が、人間および動物の組織を超音波画像形成するのに役に立つことを特徴とする薬剤。
- 前記ハロゲン化キサンテンが、約0.001%より高く約20%より低い濃度で存在することを特徴とする請求項4に記載の薬剤。
- 前記ハロゲン化キサンテンがローズ・ベンガルを含有することを特徴とする請求項4に記載の薬剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/314,840 US6986740B2 (en) | 1998-11-02 | 2002-12-09 | Ultrasound contrast using halogenated xanthenes |
PCT/US2003/039044 WO2004052407A1 (en) | 2002-12-09 | 2003-12-08 | Ultrasound contrast using halogenated xanthenes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006510677A true JP2006510677A (ja) | 2006-03-30 |
Family
ID=32505865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004559466A Pending JP2006510677A (ja) | 2002-12-09 | 2003-12-08 | ハロゲン化キサンテンを使用する超音波造影 |
Country Status (7)
Country | Link |
---|---|
US (2) | US6986740B2 (ja) |
EP (1) | EP1578454A1 (ja) |
JP (1) | JP2006510677A (ja) |
AU (1) | AU2003296371A1 (ja) |
CA (1) | CA2505975A1 (ja) |
MX (1) | MXPA05005460A (ja) |
WO (1) | WO2004052407A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050053895A1 (en) | 2003-09-09 | 2005-03-10 | The Procter & Gamble Company Attention: Chief Patent Counsel | Illuminated electric toothbrushes emitting high luminous intensity toothbrush |
EP2051776A2 (en) * | 2006-08-09 | 2009-04-29 | Koninklijke Philips Electronics N.V. | A device for and a method of activating a physiologically effective substance by ultrasonic waves, and a capsule |
US10052394B2 (en) | 2014-11-21 | 2018-08-21 | General Electric Company | Microbubble tether for diagnostic and therapeutic applications |
EP3700520B1 (en) * | 2017-11-29 | 2024-05-01 | The Rockefeller University | Combination of local and systemic therapies for enhanced treatment of dermatologic conditions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001131A1 (fr) * | 1996-07-05 | 1998-01-15 | Hitachi, Ltd. | Medicaments induisant une action ultrasonore et appareil d'utilisation de ces medicaments |
JP2001253836A (ja) * | 2000-03-09 | 2001-09-18 | Hitachi Ltd | 腫瘍治療用増感剤 |
JP2002528472A (ja) * | 1998-11-02 | 2002-09-03 | フォトゲン インク | 改良された画像化および光動力学的治療法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3868950A (en) | 1970-09-24 | 1975-03-04 | Yoshio Kato | Body treating apparatus |
US3986513A (en) | 1976-01-29 | 1976-10-19 | Joseph Lester Stuhl | Apparatus for irradiating the skin |
US4172979A (en) | 1978-06-15 | 1979-10-30 | Morrison Richard A | Method and apparatus for automatically providing radiation therapy treatment conforming to a desired volume of tissue |
US4444189A (en) | 1981-12-21 | 1984-04-24 | Seiverd Paul J | Phototherapy booth |
US4846789A (en) * | 1982-07-19 | 1989-07-11 | L. S. Van Landingham, Jr. | Combatting internal parasites in warm blooded animals |
US4490543A (en) * | 1982-11-12 | 1984-12-25 | University Of Northern Iowa Foundation | Low toxicity radiation sensitizer |
US4691332A (en) | 1983-03-14 | 1987-09-01 | American Science And Engineering, Inc. | High energy computed tomography |
US4599227A (en) | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
US4647578A (en) * | 1983-12-02 | 1987-03-03 | Sterling Drug Inc. | Phototoxic insecticidal compositions and method of use thereof |
JPS60184013A (ja) * | 1984-03-01 | 1985-09-19 | Yoshitomi Pharmaceut Ind Ltd | 点眼剤 |
JPS61169829A (ja) * | 1985-01-23 | 1986-07-31 | Fuji Photo Film Co Ltd | 光重合性組成物 |
US4712979A (en) * | 1985-11-13 | 1987-12-15 | The United States Of America As Represented By The Secretary Of The Air Force | Self-retained platform cooling plate for turbine vane |
US5690954A (en) * | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
US4856528A (en) | 1987-06-26 | 1989-08-15 | John Hopkins University | Tumor volume determination |
US5053006A (en) | 1988-04-19 | 1991-10-01 | Watson Brant D | Method for the permanent occlusion of arteries |
US5702683A (en) | 1989-01-24 | 1997-12-30 | The United States Of America As Represented By The United States Department Of Energy | Nuclear magnetic resonance contrast agents |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5008907A (en) | 1989-05-31 | 1991-04-16 | The Regents Of The University Of California | Therapy x-ray scanner |
US4973848A (en) | 1989-07-28 | 1990-11-27 | J. Mccaughan | Laser apparatus for concurrent analysis and treatment |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5368840A (en) | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5360031A (en) * | 1990-08-20 | 1994-11-01 | Truebro, Inc. | P-trap insulation and article |
US5654423A (en) | 1990-11-21 | 1997-08-05 | Regents Of The University Of California | Boronated metalloporphyrine and therapeutic methods |
US5149801A (en) | 1990-11-21 | 1992-09-22 | The Regents Of The University Of California | Boronated porphyrin compounds |
US5128139A (en) | 1991-02-15 | 1992-07-07 | Nu Skin International, Inc. | Composition containing liposome-entrapped grapefruit seed extract and method for making |
DE69230891T2 (de) * | 1991-12-11 | 2000-10-05 | Yoshitomi Pharmaceutical | Arzneimittel zur Behandlung von Autoimmunerkrankungen |
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
US5323780A (en) | 1992-08-07 | 1994-06-28 | University Of Florida Research Foundation, Inc. | Artifact-free imaging contrast agent |
US5433717A (en) | 1993-03-23 | 1995-07-18 | The Regents Of The University Of California | Magnetic resonance imaging assisted cryosurgery |
US5622422A (en) * | 1993-06-07 | 1997-04-22 | Rodgers; Nicholas A. | Flashing snorkel and scuba device |
US5445608A (en) | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
US5368031A (en) | 1993-08-29 | 1994-11-29 | General Electric Company | Magnetic resonance surgery using heat waves produced with a laser fiber |
DE4403789A1 (de) | 1994-02-03 | 1995-08-10 | Schering Ag | Mittel zur visuellen Markierung von Körpergewebe |
JP3396953B2 (ja) * | 1994-05-10 | 2003-04-14 | 千寿製薬株式会社 | 網膜疾患予防・治療剤 |
US5645423A (en) * | 1994-06-10 | 1997-07-08 | Collins, Jr.; John A. | Mandibular advancement appliance |
EP0699445A3 (en) * | 1994-08-04 | 1996-04-17 | Gakko Houjin Toin Gakuen | Process for the preparation of an ultrasonic microbubble contrast agent with a surfactant |
US5579773A (en) | 1994-09-30 | 1996-12-03 | Martin Marietta Energy Systems, Inc. | Laser-induced differential normalized fluorescence method for cancer diagnosis |
US5576013A (en) | 1995-03-21 | 1996-11-19 | Eastern Virginia Medical School | Treating vascular and neoplastic tissues |
US5591422A (en) | 1995-06-02 | 1997-01-07 | Pharmacyclics, Inc. | Texaphyrin complexes having improved functionalization |
IT1275571B (it) | 1995-07-19 | 1997-08-07 | Consiglio Nazionale Ricerche | Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori |
US6162931A (en) * | 1996-04-12 | 2000-12-19 | Molecular Probes, Inc. | Fluorinated xanthene derivatives |
US5829931A (en) * | 1996-08-09 | 1998-11-03 | S-B Power Tool Company | Removable depth guide for rotary cutting tool |
US6331286B1 (en) | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
US5832931A (en) | 1996-10-30 | 1998-11-10 | Photogen, Inc. | Method for improved selectivity in photo-activation and detection of molecular diagnostic agents |
US5829448A (en) | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
US5827186A (en) | 1997-04-11 | 1998-10-27 | Light Sciences Limited Partnership | Method and PDT probe for minimizing CT and MRI image artifacts |
ES2213899T3 (es) * | 1997-04-29 | 2004-09-01 | Amersham Health As | Agentes de contraste utilizados en tecnicas de formacion de imagen en base a la luz. |
AU8285998A (en) * | 1997-07-02 | 1999-01-25 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US7648695B2 (en) * | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
JP2003520192A (ja) | 1998-10-29 | 2003-07-02 | ザ ゼネラル ホスピタル コーポレーション | 強化された放射線治療 |
US20020001567A1 (en) * | 1998-12-21 | 2002-01-03 | Photogen, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
US6218428B1 (en) * | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
US7179449B2 (en) | 2001-01-30 | 2007-02-20 | Barnes-Jewish Hospital | Enhanced ultrasound detection with temperature-dependent contrast agents |
-
2002
- 2002-12-09 US US10/314,840 patent/US6986740B2/en not_active Expired - Lifetime
-
2003
- 2003-12-08 MX MXPA05005460A patent/MXPA05005460A/es unknown
- 2003-12-08 AU AU2003296371A patent/AU2003296371A1/en not_active Abandoned
- 2003-12-08 CA CA002505975A patent/CA2505975A1/en not_active Abandoned
- 2003-12-08 WO PCT/US2003/039044 patent/WO2004052407A1/en active Application Filing
- 2003-12-08 JP JP2004559466A patent/JP2006510677A/ja active Pending
- 2003-12-08 EP EP03812885A patent/EP1578454A1/en not_active Withdrawn
-
2004
- 2004-08-24 US US10/925,193 patent/US20050019264A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001131A1 (fr) * | 1996-07-05 | 1998-01-15 | Hitachi, Ltd. | Medicaments induisant une action ultrasonore et appareil d'utilisation de ces medicaments |
JP2002528472A (ja) * | 1998-11-02 | 2002-09-03 | フォトゲン インク | 改良された画像化および光動力学的治療法 |
JP2001253836A (ja) * | 2000-03-09 | 2001-09-18 | Hitachi Ltd | 腫瘍治療用増感剤 |
Also Published As
Publication number | Publication date |
---|---|
US6986740B2 (en) | 2006-01-17 |
US20030167006A1 (en) | 2003-09-04 |
CA2505975A1 (en) | 2004-06-24 |
EP1578454A1 (en) | 2005-09-28 |
WO2004052407A1 (en) | 2004-06-24 |
MXPA05005460A (es) | 2005-10-18 |
AU2003296371A1 (en) | 2004-06-30 |
US20050019264A1 (en) | 2005-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Izadifar et al. | Mechanical and biological effects of ultrasound: a review of present knowledge | |
Wang et al. | Study of a “biological focal region” of high-intensity focused ultrasound | |
Vlaisavljevich et al. | Effects of ultrasound frequency on nanodroplet-mediated histotripsy | |
D'Souza et al. | Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma | |
KR20140110757A (ko) | 질병을 치료하는 바이러스 불활성화 약물의 제조에서 광감각제의 용도 | |
Hysi et al. | Photoacoustic imaging biomarkers for monitoring biophysical changes during nanobubble-mediated radiation treatment | |
Luo et al. | Enhancement of ultrasound contrast agent in high-intensity focused ultrasound ablation | |
JP2008526785A (ja) | 高密度焦点式超音波療法のための増強剤および同剤のスクリーニングの方法 | |
Yin et al. | Simple structural indocyanine green-loaded microbubbles for dual-modality imaging and multi-synergistic photothermal therapy in prostate cancer | |
Dalecki | WFUMB safety symposium on echo-contrast agents: Bioeffects of ultrasound contrast agents in vivo | |
US11628315B2 (en) | Ultrasound therapy system | |
Zhao et al. | Liver haemostasis using microbubble-enhanced ultrasound at a low acoustic intensity | |
JP2008526786A (ja) | 高密度焦点式超音波療法のためのフッ化炭化水素乳濁液増強剤およびその使用 | |
CN103638534A (zh) | 一种纳米脂质超声造影剂及制备方法 | |
Takegami et al. | Erythrocytes, as well as microbubble contrast agents, are important factors in improving thermal and therapeutic effects of high-intensity focused ultrasound | |
Paek et al. | Tissue ablation using high-intensity focused ultrasound in the fetal sheep model: potential for fetal treatment | |
Yu et al. | Microbubbles improve the ablation efficiency of extracorporeal high intensity focused ultrasound against kidney tissues | |
Cai et al. | The destructive effects of high-intensity focused ultrasound on hydatid cysts enhanced by ultrasound contrast agent and superabsorbent polymer alone or in combination | |
JP2006510677A (ja) | ハロゲン化キサンテンを使用する超音波造影 | |
Hong et al. | Contrast‐enhanced ultrasonography for evaluation of blood perfusion in normal canine eyes | |
US10842889B2 (en) | Contrast composition for photoacoustic imaging and method of photoacoustic imaging using the same | |
Killam et al. | Lack of bioeffects of ultrasound energy after intravenous administration of FS069 (Optison) in the anesthetized rabbit. | |
Forte et al. | Echographic examination with new generation contrast agent of choroidal malignant melanomas | |
Gao et al. | Effect of microbubble-enhanced ultrasound on percutaneous ethanol ablation of rat walker-256 tumour | |
Cambronero et al. | Non-invasive fast, large and selective in vivo HIFU ablation of the liver with a toroidal transducer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090525 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100511 |